These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29928720)

  • 1. Emergence and spread of drug resistant influenza: A two-population game theoretical model.
    Jnawali K; Morsky B; Poore K; Bauch CT
    Infect Dis Model; 2016 Oct; 1(1):40-51. PubMed ID: 29928720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral resistance and the control of pandemic influenza.
    Lipsitch M; Cohen T; Murray M; Levin BR
    PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
    Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
    PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs.
    McCaw JM; Wood JG; McCaw CT; McVernon J
    PLoS One; 2008 Jun; 3(6):e2362. PubMed ID: 18523549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the global transmission of antiviral-resistant influenza viruses.
    Chao DL
    Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):58-62. PubMed ID: 23279898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the effects of drug resistant influenza virus in a pandemic.
    Brockmann SO; Schwehm M; Duerr HP; Witschi M; Koch D; Vidondo B; Eichner M
    Virol J; 2008 Oct; 5():133. PubMed ID: 18973656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.
    Leung K; Lipsitch M; Yuen KY; Wu JT
    Lancet Infect Dis; 2017 Mar; 17(3):339-347. PubMed ID: 27914853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traveling Waves and Estimation of Minimal Wave Speed for a Diffusive Influenza Model with Multiple Strains.
    Chen G; Fu X; Sun M
    Bull Math Biol; 2020 Sep; 82(9):121. PubMed ID: 32920726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use.
    Arino J; Bowman CS; Moghadas SM
    BMC Infect Dis; 2009 Jan; 9():8. PubMed ID: 19161634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drivers and consequences of influenza antiviral resistant-strain emergence in a capacity-constrained pandemic response.
    Dafilis MP; Moss R; McVernon J; McCaw J
    Epidemics; 2012 Dec; 4(4):219-26. PubMed ID: 23351374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the evolution of drug resistance in the presence of antiviral drugs.
    Wu J; Yan P; Archibald C
    BMC Public Health; 2007 Oct; 7():300. PubMed ID: 17953775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty.
    Greer AL; Schanzer D
    PLoS One; 2013; 8(6):e67253. PubMed ID: 23805303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.
    Handel A; Longini IM; Antia R
    J Theor Biol; 2009 Jan; 256(1):117-25. PubMed ID: 18952105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-exposure prophylaxis during pandemic outbreaks.
    Moghadas SM; Bowman CS; Röst G; Fisman DN; Wu J
    BMC Med; 2009 Dec; 7():73. PubMed ID: 19954514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the effectiveness of interventions used during the 2009 A/H1N1 influenza pandemic.
    Halder N; Kelso JK; Milne GJ
    BMC Public Health; 2010 Mar; 10():168. PubMed ID: 20346187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
    Ruangrung K; Suptawiwat O; Maneechotesuwan K; Boonarkart C; Chakritbudsabong W; Assawabhumi J; Bhattarakosol P; Uiprasertkul M; Puthavathana P; Wiriyarat W; Jongkaewwattana A; Auewarakul P
    J Virol; 2016 May; 90(9):4637-4646. PubMed ID: 26912622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The global spread of drug-resistant influenza.
    Chao DL; Bloom JD; Kochin BF; Antia R; Longini IM
    J R Soc Interface; 2012 Apr; 9(69):648-56. PubMed ID: 21865253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
    Nguyen HT; Fry AM; Gubareva LV
    Antivir Ther; 2012; 17(1 Pt B):159-73. PubMed ID: 22311680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-wide emergence of antiviral resistance during pandemic influenza.
    Moghadas SM; Bowman CS; Röst G; Wu J
    PLoS One; 2008 Mar; 3(3):e1839. PubMed ID: 18350174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies.
    Hsieh NH; Lin YJ; Yang YF; Liao CM
    Infect Drug Resist; 2017; 10():215-226. PubMed ID: 28790857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.